| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. Built for biotech. |
Today's Rundown Merck inks $773M Tilos takeout to bag TGFβ cancer programs Amid BMS R&D shuffle, F-star nabs its immuno-oncology executive Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist [Sponsored] Advancing a Diabetes Multi-Registration Program Janssen inks nference AI research pact ADA: NGM backs up case for once-monthly dosing of Merck-partnered NASH drug Special Report—The top 20 highest-paid biopharma CEOs of 2018 Featured Story | | | Monday, June 10, 2019 Merck has struck a $773 million detail to buy Tilos Therapeutics. The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the latent TGFβ complex. |
|
|
Top Stories Monday, June 10, 2019 Last week, Bristol-Myers Squibb announced it was changing up its R&D structure and personnel as it subsumes new buy Celgene, and one of its key executives has now jumped ship to a small British biotech. Monday, June 10, 2019 Eli Lilly is planning to test its closely watched diabetes drug tirzepatide in a phase 2b nonalcoholic steatohepatitis (NASH) trial. The expansion is driven by midphase Type 2 diabetes data suggesting the dual GIP and GLP-1 receptor agonist improves markers associated with NASH. Monday, June 10, 2019 Read the case study to learn how Covance helped a sponsor who wanted to get all sites for a 2,700 patient study up and running as quickly as possible. Covance leveraged their proprietary historical investigator performance database to see which investigators outperformed their peers on a consistent basis and had the capacity to run multiple studies at the same time. Monday, June 10, 2019 Looking to broaden its use of artificial intelligence to help lock down its R&D work, Johnson & Johnson’s biotech unit Janssen has penned a new deal with AI specialist nference. Monday, June 10, 2019 At the American Diabetes Association meeting, NGM Biopharmaceuticals presented new data from a phase 1b trial to back up what it and partner Merck hope will be a selling point for their experimental drug to treat nonalcoholic steatohepatitis in patients with or without diabetes: a convenient dosing schedule. Monday, June 10, 2019 As spring rolls on each year, proxy filings pile up, disclosing executive pay for the prior year. And as in past years, FiercePharma has tracked the info to present the top CEO pay packages in biopharma, ranging from nearly $60 million in 2018 down to $16 million. | This week's sponsor is Cobra Biologics. | | |
Cobra provides expert scale up and manufacturing of customers’ live biotherapeutic microbiota products, manufacturing to cGMP standards for clinical and commercial scale. We also offer DNA and viral vector services, with experienced project teams nurturing customers’ products within GMP approved facilities. Visit our website to find out more. |
Resources Sponsored by: AlphaSense What is agile competitive intelligence, and how can it help take market research to the next level? Sponsored by: Reprints Desk, Inc. Get 5 quick tips for faster research and better results! Sponsored by: Blue Latitude Health In this publication, Blue Latitude Health maps the journey of stakeholders impacted by the rise of precision medicine today. Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Increase Safety & Flexibility with Flow Chemistry Sponsored by: Veeva IONIS shares best practices for implementing an end-to-end RIM solution in this on-demand webinar. Watch now. Sponsored by: WCG Increasingly complex clinical trials place a tremendous burden on study sites, exacerbating already-troubling recruitment and enrollment issues. Overwhelmed, many sites may not be up to the task or have the appropriate infrastructure, creating costly delays that keep new therapies from patients. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 